同步放化疗与序贯放化疗对食管癌预后影响的Meta分析  

Concurrent Radiochemotherapy Versus Sequential Radiochemotherapy for Esophageal Cancer: a Meta-analysis

作　　者：杨健筌 郭文[2] 李光明 

机构地区：[1]泸州医学院,646000 [2]四川省南充卫生学校,637000 [3]南充市中心医院.川北医学院第二临床医学院,637000

出　　处：《实用癌症杂志》2016年第4期588-594,共7页The Practical Journal of Cancer

摘　　要：目的评价同步放化疗(CCRT)与序贯放化疗(SCRT)治疗食管癌的远期疗效。方法计算机检索The Cochrane Library、Pubmed、Embase、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、维普中文科技期全文数据库(VIP)和万方数据库,对符合纳入标准的随机对照试验进行方法学质量评价,采用Rev Man 5.3进行Meta分析。结果共纳入22个研究1933例患者,结果显示,同步放化疗组1年生存率、2年生存率、3年生存率、1年疾病局部控制率、2年疾病局部控制率、3年疾病局部控制率[OR=2.41,95%CI(1.48,3.91),P=0.0004]优于序贯放化疗组,在远处转移方面,两组无差别。结论同步放化疗治疗食管癌的1、2、3年生存率,1、2、3、年局部局部控制率优于序贯放化疗,但受纳入研究的质量的影响,上述结论尚需更多高质量的临床试验来进一步证实。Objective To evaluate the long-term efficacy of concurrent radiochemotherapy（CCRT） versus sequential ra- diochemotherapy（SCRT） for esophageal cancer. Methods The Cochrane Library, Pubmed, Embase, CBM, CNKI, VIP, Wanfang Database were searched, and the methodological quality assessment of RCTs was conducted according to the methods of＇ Cochrane collaboration. The meta-analysis were performed by using the Revman 5.3 software. Results 22 RCTs containing 1933 patients were finally included. 1-year survival rate （ P 〈 0. 00001 ）, 2-year survival rate （ P 〈 0. 00001 ） , 3-year survival rate （ P 〈 0.00001 ）, 1 -year local control rate （ P = 0.0009 ） , 2-year local control rate （ P = 0. 0006 ） , 3-year local control rate （ P = 0. 0004 ） of CCRT group were superior to SCRT group. There was no significant difference in the distant metastasis between the 2 groups（ P = 0.38）. Conclusion 1-,2-,3-year survival rates and 1-,2-,3-year local control rates of patients with esophageal cancer treated by CCRT are superior to SCRT. For the quality of included study, the conclusion needs more high-quality clinical researches.

关 键 词：食管癌 同步放化疗 序贯放化疗 

分 类 号：R735.1[医药卫生—肿瘤]